# Single Dose Two-periods Crossover Bioequivalence Study of Darifenacin Tablets in Healthy Volunteers.

> **NCT01227811** · PHASE1 · UNKNOWN · sponsor: **Center for Clinical Pharmacology Research Bdbeq S.A.** · enrollment: 24 (estimated)

## Conditions studied

- Bioequivalency

## Interventions

- **DRUG:** Darifenacin
- **DRUG:** Darifenacin

## Key facts

- **NCT ID:** NCT01227811
- **Lead sponsor:** Center for Clinical Pharmacology Research Bdbeq S.A.
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2010-11
- **Primary completion:** 2010-12
- **Final completion:** 2011-03
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2010-10-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01227811

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01227811, "Single Dose Two-periods Crossover Bioequivalence Study of Darifenacin Tablets in Healthy Volunteers.". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01227811. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*